Finding the hidden signals in ALS.
IDM integrates clinical, genomic, biomarker and real-world data to uncover meaningful patterns in ALS progression, validate promising signals and translate insights toward better research, trials and therapies.
Built with leaders in clinical intelligence,
ALS research, patient advocacy, and data science.
ALS is not one disease journey.
Those differences may contain some of the most important signals in ALS.
People living with ALS can experience dramatically different patterns of onset, progression, survival, and treatment response. Yet the data needed to understand those differences often sits across disconnected studies, platforms, and institutions.
Traditional analysis can miss important signals when distinct patient groups are treated as a single average population.
IDM is working to make those differences visible.
From fragmented data to actionable insight.
Harmonize
Connect fragmented ALS datasets.
Discover
Identify progression patterns, patient subgroups, outliers and potential biological signals.
Validate
Test promising signals across datasets, methodologies and scientific evidence.
Translate
Apply validated insights toward biomarkers, therapeutic development and clinical trials.
A personal diagnosis became a public mission.
IDM began with a question inspired by Aaron Lazar's experience living with ALS: why do some people progress differently from others—and what might those differences teach us?
Read Our StoryFrom ALS intelligence to real-world application.
Therapeutic Development
Identify biological mechanisms and actionable patient subgroups.
Clinical Trials
Support better stratification and retrospective trial intelligence.
Biomarkers
Connect progression phenotypes with genomic and biological signals.
Research
Enable cross-dataset analysis that no single dataset can provide alone.
Progress requires collaboration.
IDM works alongside leading organizations and researchers to accelerate understanding and improve outcomes.
Data & Analytics
Clinical & Scientific Guidance
ALS Research & Advocacy
Academic & Health System Partners
Therapeutic & Industry Collaborators
Latest News
View all news →Media
Oct 7, 2025
Aaron Lazar on Living With ALS, Filming 'Countdown' With Eric Dane and Launching New Podcast
Read More →Partnerships
Nov 5, 2025
The Impossible Dream Machine Partners with PCCI to Advance Neurodegenerative Disease Research
Read More →The next breakthrough may already exist inside the data.
IDM is engaging researchers, biotechnology companies, data partners, funders, and members of the ALS community who believe more precise insight can lead to better therapeutic decisions.